Tag: stage

VANCOUVER, BC, July 23, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce...

Group CFO of SingularityNET Foundation since 2020, scaling the ecosystem from $40M USD market cap to multi-billion USD market cap $90M USD in digital...

Beauty meets intelligent tech: L'Oréal Turkey unlocks faster, more consistent creative production with AdCreative.ai ISTANBUL and PARIS, July 23, 2025 /PRNewswire/ -- L'Oréal Turkey has partnered with...

LOS ANGELES, July 23, 2025 /PRNewswire/ -- Viewers of Public Television are in for an enlightening experience as "Empowered with Meg Ryan" presents a...

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billionRecorded Q2'25 consolidated operating profit of KRW 475.6 billionSolid momentum sustained through capacity ramp-up and stable project...

CEO Dr. Michael Fübi's visit reinforces India's growing role in shaping global compliance standards, sustainable industries, and future-ready workforce development. BANGALORE, India, July 23,...

NEW YORK, July 22, 2025 /PRNewswire/ -- Expert Consumers has recognized QuickBooks as a leading AI bookkeeping solution in its latest 2025 software review. The...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

SINGAPORE, July 23, 2025 /PRNewswire/ -- On 17 July 2025, Giti Tire was honoured to be conferred as a 3 heart Company of Good at...

The "Switch Your Story" campaign is Schwarzkopf's first-ever collaboration with The Walt Disney Studios LOS ANGELES, July 22, 2025 /PRNewswire/ -- Schwarzkopf®, an authority in hair...

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

ASX Release $132M Treasury Build in Q4 FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX - Westgold or the Company) is pleased to report results...